Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Conditions

Arthritis, Rheumatoid 10Psoriasis 6Leukemia 5Lymphoma, Follicular 4Myelodysplastic Syndromes 3Inflammation 3Asthma 3Arthritis, Juvenile 3Vasculitis 2Uveitis 2Respiratory Distress Syndrome 2Recurrence 2Prostatic Neoplasms 2Pneumonia 2Neuroblastoma 2Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Granulomatosis with Polyangiitis 2Bronchiolitis Obliterans 2Wilms Tumor 1Temporomandibular Joint Disorders 1Stomatitis 1Spondylitis, Ankylosing 1Spondylarthritis 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1

Interventions

Fluticasone-Salmeterol Drug Combination 3Etanercept 3Fluticasone 2Budesonide 2Beclomethasone 2perflutren 1laninamivir 1fluticasone-formoterol 1Sulfur Hexafluoride 1Prednisolone 1NVP-QAV680 1Lysine Acetyltransferase 5 1Health Information Exchange 1Formoterol Fumarate 1Exercise 1Escitalopram 1CS 8958 1Budesonide, Formoterol Fumarate Drug Combination 1Bronchial Thermoplasty 1Blood Specimen Collection 1Azithromycin 1Amoxicillin-Potassium Clavulanate Combination 1Albuterol 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Asthma × Etanercept × Clear all
NCT00001893 2017-07-02

Study of TNFR:Fc (Enbrel) in the Treatment of Asthma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
150 enrolled

Asthma

NCT00141791 2009-08-07

Study Evaluating Etanercept in Moderate to Severe Asthma

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
120 enrolled

Asthma

NCT00276029 2006-05-04

TNF Alpha in Refractory Asthma

University Hospitals, Leicester

Phase NA Completed
10 enrolled

Asthma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡